Prostate Cancer Clinical Trial
Official title:
Robot-assisted vs Laparoscopic Radical Prostatectomy for Prostate Cancer Treatment
This study is to compare the outcomes of robotic-assisted laparoscopic radical prostatectomy (RARP) and laparoscopic radical prostatectomy (LRP) for prostate cancer treatment in terms of perioperative surgical, functional and oncological outcomes.
Status | Recruiting |
Enrollment | 80 |
Est. completion date | December 31, 2020 |
Est. primary completion date | December 31, 2020 |
Accepts healthy volunteers | No |
Gender | Male |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: 1. Adult men aged 18 years and over; 2. Undergoing RARP or LRP. prostatectomy for prostate cancer at Binh Dan Hospital; 3. Clinically suitable for radical prostatectomy (cT1-3, No, Mo); 4. Cognitively able to give written informed consent for participation; 5. Elective procedure. Exclusion Criteria: 1. The patient lacks the ability to consent for themselves; 2. Patients unwilling to undergo pre- and post-operative evaluation according to the protocol; |
Country | Name | City | State |
---|---|---|---|
Vietnam | Binh Dan Hospital | Ho Chi Minh City |
Lead Sponsor | Collaborator |
---|---|
Binh Dan Hospital |
Vietnam,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The console time | The time which surgeon spends on the robot console by minuite | During the surgery | |
Primary | Mean of blood loss | Milliliter | During the surgery | |
Primary | Perioperative transfusion rate (%) | The number of cases which will be transfused. | Up to 1 month after operation | |
Primary | The rate of positive surgical margins, extracapsular extension, seminal vesicle invasion, (5)perineural invasion, the number of lymph node yield and node involvement, | Number of cases, based on the result of pathology. | Up to 1 week after operation | |
Primary | Number of blood units transfused | Milliliter | Up to 1 week after operation | |
Primary | the rate of conversion to open surgery, the rate of intraoperative incidents (%), | Percentage | Up to 1 weeks after the surgery. | |
Primary | The postoperative recovery parameters using Numeric Pain Rating Scale (NPRS), | The NPRS is a segmented numeric version of the visual analog scale (VAS) in which a respondent selects a whole number (0-10 integers) that best reflects the intensity of pain, in a total of 10 points, higher score means worse, with 0 means no pain and 10 is the worst pain. The mean score will be calculated to reflect the post-operative pain. | Up to 3 month after surgery | |
Primary | Change of hemoglobin from baseline | (mg/mL) | Up to 1 week after operation | |
Primary | The drainage time | (day), | Up to 3 months after surgery | |
Primary | To assess urethral catheter time, urethral catheter time | (day) | Up to 3 months after surgery | |
Primary | To assess bowel movement recovery time, | (day) | Up to 1 week after surgery | |
Primary | To assess postoperative hospital stay | (day) | Up to 1 month after surgery | |
Primary | The rate of postoperative complications (including infections) | Percentage | in day 3, day 7, and 1 month after surgery. | |
Primary | PSA level in blood | (mg/mL) | Before operation | |
Primary | PSA level in blood | (mg/mL) | 6 weeks post-operation | |
Primary | PSA level in blood | (mg/mL) | 3 months post-operation | |
Primary | PSA level in blood | (mg/mL) | 6 months post-operation | |
Primary | PSA level in blood | (mg/mL) | 12 months post-operation | |
Primary | local and regional recurrences on sonography | including ultrasound when PSA rising or any indication of recurrent | through study completion, an average of 1 year | |
Primary | local and regional recurrences, on MRI | including MRI when PSA rising or any indication of recurrent | through study completion, an average of 1 year | |
Primary | local and regional recurrences, on PET Scan | including PET Scan, when PSA rising or any indication of recurrent | through study completion, an average of 1 year | |
Secondary | Evaluating the pre and postoperative lower urinary tract symptoms using Full score of International Prostate Symptoms Scores (IPSS) | It contains seven questions related to symptoms related to BPH and one question related to the patient's perceived quality of life. The symptoms must have been experienced in the last month and each answer is scored from 0 to 5 for a maximum score of 35 points. The sum score will be calculated and the mean score will be evaluated. | Preoperative | |
Secondary | Evaluating the pre and postoperative lower urinary tract symptoms using International Prostate Symptoms Scores (IPSS) | It contains seven questions related to symptoms related to BPH and one question related to the patient's perceived quality of life. The symptoms must have been experienced in the last month and each answer is scored from 0 to 5 for a maximum score of 35 points. The sum score will be calculated and the mean score will be evaluated. | 3 months postoperative | |
Secondary | Evaluating the pre and postoperative lower urinary tract symptoms using Full score of International Prostate Symptoms Scores (IPSS) | It contains seven questions related to symptoms related to BPH and one question related to the patient's perceived quality of life. The symptoms must have been experienced in the last month and each answer is scored from 0 to 5 for a maximum score of 35 points. The sum score will be calculated and the mean score will be evaluated. | 6 months, postoperative | |
Secondary | Evaluating the pre and postoperative lower urinary tract symptoms using Full score of International Prostate Symptoms Scores (IPSS) | It contains seven questions related to symptoms related to BPH and one question related to the patient's perceived quality of life. The symptoms must have been experienced in the last month and each answer is scored from 0 to 5 for a maximum score of 35 points. The sum score will be calculated and the mean score will be evaluated. | 12 months postoperative. | |
Secondary | Erectile function assessments questionnaires and scoring using Index of Erectile Function Questionnaire, IIEF5, full score | The 15-question International Index of Erectile Function (IIEF) Questionnaire is a validated, multi-dimensional, self-administered investigation that has been found useful in the clinical assessment of erectile dysfunction and treatment outcomes in clinical trials. A score of 0-5 is awarded to each of the 15 questions that examine the 4 main domains of male sexual function: erectile function, orgasmic function, sexual desire and intercourse satisfaction. The score ranges from 22 - 25 for Normal erectile function (no ED), 17 - 21 for Mild ED, 12 - 16 for Mild to moderate ED, 8 - 11 for Moderate ED, and from 1 - 7 for Severe ED (5 - 7, if a man had no opportunity to engage in sexual activity). The mean score will be calculated. | Preoperative | |
Secondary | Erectile function assessments questionnaires and scoring using Index of Erectile Function Questionnaire, IIEF5, full score | The 15-question International Index of Erectile Function (IIEF) Questionnaire is a validated, multi-dimensional, self-administered investigation that has been found useful in the clinical assessment of erectile dysfunction and treatment outcomes in clinical trials. A score of 0-5 is awarded to each of the 15 questions that examine the 4 main domains of male sexual function: erectile function, orgasmic function, sexual desire and intercourse satisfaction. The score ranges from 22 - 25 for Normal erectile function (no ED), 17 - 21 for Mild ED, 12 - 16 for Mild to moderate ED, 8 - 11 for Moderate ED, and from 1 - 7 for Severe ED (5 - 7, if a man had no opportunity to engage in sexual activity). The mean score will be calculated. | 3 months, postoperative | |
Secondary | Erectile function assessments questionnaires and scoring using Index of Erectile Function Questionnaire, IIEF5, full score | The 15-question International Index of Erectile Function (IIEF) Questionnaire is a validated, multi-dimensional, self-administered investigation that has been found useful in the clinical assessment of erectile dysfunction and treatment outcomes in clinical trials. A score of 0-5 is awarded to each of the 15 questions that examine the 4 main domains of male sexual function: erectile function, orgasmic function, sexual desire and intercourse satisfaction. The score ranges from 22 - 25 for Normal erectile function (no ED), 17 - 21 for Mild ED, 12 - 16 for Mild to moderate ED, 8 - 11 for Moderate ED, and from 1 - 7 for Severe ED (5 - 7, if a man had no opportunity to engage in sexual activity). The mean score will be calculated. | 6 months, postoperative. | |
Secondary | Erectile function assessments questionnaires and scoring using Index of Erectile Function Questionnaire, IIEF5, full score | The 15-question International Index of Erectile Function (IIEF) Questionnaire is a validated, multi-dimensional, self-administered investigation that has been found useful in the clinical assessment of erectile dysfunction and treatment outcomes in clinical trials. A score of 0-5 is awarded to each of the 15 questions that examine the 4 main domains of male sexual function: erectile function, orgasmic function, sexual desire and intercourse satisfaction. The score ranges from 22 - 25 for Normal erectile function (no ED), 17 - 21 for Mild ED, 12 - 16 for Mild to moderate ED, 8 - 11 for Moderate ED, and from 1 - 7 for Severe ED (5 - 7, if a man had no opportunity to engage in sexual activity). The mean score will be calculated. | 12 months postoperative | |
Secondary | The quality of life questionnaires and scoring using the the Short Form (36) Health Survey questionnaire | The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability i.e., a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability. The mean score will be calculated. | Preoperative | |
Secondary | The quality of life questionnaires and scoring using the the Short Form (36) Health Survey questionnaire | The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability i.e., a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability. The mean score will be calculated. | 3 months, postoperative. | |
Secondary | The quality of life questionnaires and scoring using the the Short Form (36) Health Survey questionnaire | The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability i.e., a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability. The mean score will be calculated. | 6 months, postoperative | |
Secondary | The quality of life questionnaires and scoring using the the Short Form (36) Health Survey questionnaire | The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability i.e., a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability. The mean score will be calculated. | 12 months postoperative |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05613023 -
A Trial of 5 Fraction Prostate SBRT Versus 5 Fraction Prostate and Pelvic Nodal SBRT
|
Phase 3 | |
Recruiting |
NCT05540392 -
An Acupuncture Study for Prostate Cancer Survivors With Urinary Issues
|
Phase 1/Phase 2 | |
Recruiting |
NCT05156424 -
A Comparison of Aerobic and Resistance Exercise to Counteract Treatment Side Effects in Men With Prostate Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT03177759 -
Living With Prostate Cancer (LPC)
|
||
Completed |
NCT01331083 -
A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer
|
Phase 2 | |
Recruiting |
NCT05540782 -
A Study of Cognitive Health in Survivors of Prostate Cancer
|
||
Active, not recruiting |
NCT04742361 -
Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer
|
Phase 3 | |
Completed |
NCT04400656 -
PROState Pathway Embedded Comparative Trial
|
||
Completed |
NCT02282644 -
Individual Phenotype Analysis in Patients With Castration-Resistant Prostate Cancer With CellSearch® and Flow Cytometry
|
N/A | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT06305832 -
Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer
|
Phase 2 | |
Recruiting |
NCT05761093 -
Patient and Physician Benefit/ Risk Preferences for Treatment of mPC in Hong Kong: a Discrete Choice Experiment
|
||
Completed |
NCT04838626 -
Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection
|
Phase 2/Phase 3 | |
Recruiting |
NCT03101176 -
Multiparametric Ultrasound Imaging in Prostate Cancer
|
N/A | |
Completed |
NCT03290417 -
Correlative Analysis of the Genomics of Vitamin D and Omega-3 Fatty Acid Intake in Prostate Cancer
|
N/A | |
Completed |
NCT00341939 -
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
|
||
Completed |
NCT01497925 -
Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer
|
Phase 1 | |
Recruiting |
NCT03679819 -
Single-center Trial for the Validation of High-resolution Transrectal Ultrasound (Exact Imaging Scanner ExactVu) for the Detection of Prostate Cancer
|
||
Completed |
NCT03554317 -
COMbination of Bipolar Androgen Therapy and Nivolumab
|
Phase 2 | |
Completed |
NCT03271502 -
Effect of Anesthesia on Optic Nerve Sheath Diameter in Patients Undergoing Robot-assisted Laparoscopic Prostatectomy
|
N/A |